Loading...
Bicalutamide, a nonsteroidal oral antiandrogen, has been used for more than 2 decades in men with prostate cancer, both in combination with luteinizing hormone–releasing hormone (LHRH) analogues for those with metastatic disease and as a single agent in second-line hormonal therapy for those with disease progression following LHRH analogue therapy. Enzalutamide is a novel androgen receptor inhibitor approved in the treatment of metastatic castration-resistant prostate cancer (mCRPC)
To compare the efficacy and safety of bicalutamide and enzalutamide, international investigators conducted an industry-sponsored, randomized, double-blind, phase II trial involving 375 men with mCRPC that had progressed on androgen-deprivation therapy (ADT). Pati…